Peptide5 (TFA)

• Description:

  Peptide5 TFA, a connexin 43 mimetic peptide, reduces animals swelling, astrogliosis, and neuronal cell death after spinal cord injury. Peptide5 TFA also inhibits NLRP3 inflammasome, and is an anti-inflammatory agent[1][2][3].

• UNSPSC:

  12352209

• Target:

  Connexin; Gap Junction Protein; NOD-like Receptor (NLR)

• Type:

  Peptides

• Related Pathways:

  Cytoskeleton; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/peptide5-tfa.html

• Purity:

  98.87

• Solubility:

  H2O : 50 mg/mL (ultrasonic)

• Smiles:

  OC(C(F)(F)F)=O.C[C@@H](O)[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H](CCC(O)=O)NC([C@H]([C@H](O)C)NC([C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CC2=CC=CC=C2)NC([C@H](CS)NC([C@H](CC(O)=O)NC([C@H](C(C)C)N)=O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O)=O)=O

• Molecular Formula:

  C62H99F3N16O22S

• Molecular Weight:

  1509.60

• References & Citations:

  [1]Simon J O'Carroll, et al. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. Cell Commun Adhes. 2008 May;15 (1) :27-42.|[2]Yilin Mao, et al. Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. Exp Brain Res. 2017 Oct;235 (10) :3033-3048.|[3]Tonkin RS, et al. Attenuation of mechanical pain hypersensitivity by treatment with Peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice. Exp Neurol. 2018 Feb;300:1-12.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported